Virtual Presentation

Weighing the Options for First-Line Antiretroviral Therapy

Source: Weighing the Options: Choosing the Initial Antiretroviral Regimen

Weighing the Options for First-Line Antiretroviral Therapy

Faculty:

Joseph J. Eron, Jr., MD

CREDIT INFORMATION

Release Date: July 09, 2009

Expiration Date: July 08, 2010

Status: The activity is not currently available for credit.

Learning Objectives

Upon completion of this activity, participants should be able to:

Apply recent clinical trial data comparing NNRTI- vs PI-based regimens when selecting initial therapy for HIV-infected patients
Differentiate between boosted PIs based on efficacy, adverse effects, dosing convenience, and potential drug-drug interactions
Describe individual patient cases in which abacavir/lamivudine may be preferable to tenofovir/emtricitabine and vice versa
Summarize recent data on the efficacy, safety, and resistance profile of novel classes for the initial treatment of HIV infection

CCO Virtual Presentations combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.

Abstract

Click here to view abstract

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.